Evidence map›Paper›PMID 39597939›Full record

ReviewJournal of clinical medicine2024

The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population-A Narrative Review.

Simone Szymczyk, Katarzyna Mączka, Lidia Mądrzak, Monika Grymowicz, Roman Smolarczyk

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Simone SzymczykDepartment of Gynecological Endocrinology, Clinical Hospital of Duchess Anna Mazowiecka, Medical University of Warsaw, 2 Karowa Street, 00-315 Warsaw, Poland.ORCID 0009-0002-7831-3667
Katarzyna MączkaDepartment of Gynecological Endocrinology, Clinical Hospital of Duchess Anna Mazowiecka, Medical University of Warsaw, 2 Karowa Street, 00-315 Warsaw, Poland.ORCID 0009-0007-0223-6892
Lidia MądrzakDepartment of Gynecological Endocrinology, Clinical Hospital of Duchess Anna Mazowiecka, Medical University of Warsaw, 2 Karowa Street, 00-315 Warsaw, Poland.
Monika GrymowiczDepartment of Gynecological Endocrinology, Clinical Hospital of Duchess Anna Mazowiecka, Medical University of Warsaw, 2 Karowa Street, 00-315 Warsaw, Poland.ORCID 0000-0002-3161-0886
Roman SmolarczykDepartment of Gynecological Endocrinology, Clinical Hospital of Duchess Anna Mazowiecka, Medical University of Warsaw, 2 Karowa Street, 00-315 Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrently, progesterone is notably absent from conventional feminizing hormone therapies for transgender women. Anecdotal reports indicate the potential for health advantages following the incorporation of progesterone into treatment regimens. The primarily female hormone, progesterone naturally surges in women during the menstrual luteal phase. When administered exogenously, it may expedite bodily changes that are pivotal for gender transition. Progesterone holds promise as a potential remedy for various health conditions prevalent in the transgender woman population.

methodsThis narrative review synthesizes existing literature and presents a comprehensive account of the administration of exogenous progesterone in transgender women. A literature search was conducted using the PubMed, Embase, ScienceDirect, and ResearchGate databases. The following keywords were used in the search: progesterone, transgender, breast neoplasms, lactation, prostate, testicular neoplasms, and thrombosis. These terms were combined using Boolean operators. The results of the initial search were screened by three independent reviewers based on their relevance to the topic under study.

resultsA total of 104 studies were initially identified as meeting the criteria for inclusion. Following an assessment based on the contents of the title, abstract, and full text, 39 studies were deemed eligible for inclusion. A critical examination of health outcomes was conducted across key sections, including breast development, mental health, lactation, cancer risk (breast and prostate), thrombosis, and nervous and other systems. DISCUSSION: The use of progesterone in the transgender woman population is a topic that has yet to be sufficiently researched. The limited sample size, short follow-up periods, and lack of randomization restrict the potential for achieving a robust scientific evidence base. In order to gain a fuller understanding of this topic, findings from studies on contraception, hormone replacement therapy, and animal models were considered.

conclusionsProgesterone may have a beneficial effect on the bodies of transgender women without significant adverse health effects. Further investigation through well-designed studies is recommended. Randomized controlled trials that include various dosages, broad and long-term effects, and precise demographics are needed. There is an immediate need for more knowledge to create appropriate patent and clinical practice guidelines.

Indexed as

feminizationGAHThormoneMTFprogesteronetranstransgender

Identifiers

PMID39597939
PMCPMC11594581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.